Xuewen Ma

Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).

Carolina Schinke, Cyrille Touzeau, Monique C. Minnema et al. · Journal of Clinical Oncology · 2023 · 84 citations

Clinical Immunology, Immunodeficiencies, Immunology +24

Applications of High Throughput Microsomal Stability Assay in Drug Discovery

Li Di, Edward H. Kerns, Xuewen Ma et al. · Combinatorial Chemistry & High Throughput Screening · 2008 · 68 citations

Pharmaceutical Research, High Throughput, High Throughput Assays +19

Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Amrita Krishnan, Monique C. Minnema, Jesús G. Berdeja et al. · Blood · 2021 · 51 citations

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study

Ajai Chari, Cyrille Touzeau, Carolina Schinke et al. · The Lancet Haematology · 2025 · 51 citations · Full text

Hematological Malignancy, Medicine, Hematology +7

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

Ajai Chari, Cyrille Touzeau, Carolina Schinke et al. · Blood · 2022 · 41 citations